| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Milton H. Werner last filed a Form 4 in January 2025, as President and CEO at IKT. Milton H. Werner's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Milton H. Werner's trades have earned a below-average insider score of 24/100 across 4 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -38.7%.
At the last filing, the largest reported position was 5,335,433 shares of IKT. Net of sales, the IKT filings show accumulation of 43,589 shares.
Milton H. Werner has 14 Form 4 filings on record from December 2020 to January 2025, all as President and CEO at Inhibikase Therapeutics (IKT), 2020–2025.
The 38 reported transactions were 17 option or other derivative awards, 9 dispositions back to the company, 8 open-market purchases and 3 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 4 purchases worth about $61K and no sales.
The largest open-market purchase was 23,589 shares of IKT at an average $1.97 on November 17, 2021, about $47K. Twelve months later IKT was down 65%.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | IKT Inhibikase Therapeutics, Inc. | President and CEO | Buy | 5,000 | $0.80 | $4,000.00 | - | -32.3% | -53.2% | |
| May 27, 2022 | IKT Inhibikase Therapeutics, Inc. | President and CEO | Buy | 5,000 | $0.98 | $4,880.00 | - | -6.0% | -34.2% | |
| May 20, 2022 | IKT Inhibikase Therapeutics, Inc. | President and CEO | Buy | 10,000 | $0.60 | $6,000.00 | +0.2% | +22.2% | -2.5% | |
| Nov 17, 2021 | IKT Inhibikase Therapeutics, Inc. | President and CEO | Buy | 23,589 | $1.97 | $46,558.14 | New | -37.4% | -64.9% |